Session Abstract – PMWC 2022 Silicon Valley

 Session Chair Profile

Ph.D., Professor of Health Economics and Founding Director, UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), Department of Clinical Pharmacy, UCSF

Biography
Kathryn A. Phillips PhD is Professor of Health Economics and Health Services Research, Department of Clinical Pharmacy, University of California San Francisco. She founded and leads the UCSF Center for Translational and Policy Research on Precision Medicine (TRANSPERS), which focuses on developing objective evidence on how to implement precision medicine into health care so that it is effective, efficient, and equitable. Kathryn has published over 150 peer-reviewed articles in major journals including JAMA, New England Journal of Medicine, Science, and Health Affairs. She has had continuous funding from NIH as a Principal Investigator for over 25 years and was recently awarded a 5-year, $5M NIH grant to examine payer coverage and economic value for emerging genomic technologies (e.g., cell-free DNA tests and tests based on polygenic risk scores). Kathryn serves on the editorial boards for Health Affairs, Value in Health, JAMA Internal Medicine, Genetics in Medicine; is a member of the National Academy of Medicine Roundtable on Genomics and Precision Health; and has served on the governing Board of Directors for GenomeCanada and as an advisor to the FDA, CDC, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to many diagnostics, sequencing, and pharmaceutical companies as well as venture capitalists. Kathryn is Chair of the Global Economics and Evaluation of Clinical Sequencing Working Group, and a member of an evidence review committee for the Institute for Clinical and Economic Review (ICER). Her work has been quoted by the Washington Post, Wall Street Journal, New York Times, CNBC, Reuters, Newsweek, and other major news outlets.


 Speaker Profile

M.D., Chief Medical Officer, SVP, llumina

Biography
Dr. Febbo is responsible for developing and executing medical strategy to drive genomic testing into healthcare practice. Before joining Illumina, Dr. Febbo served as CMO of Genomic Health. Prior to his years at Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the UCSF, where his laboratory focused on using genomics to understand clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. Dr. Febbo holds an M.D. from UCSF. Completing his internal medicine residency at the Brigham and Women’s Hospital and fellowship in oncology at the Dana-Farber Cancer Institute. While an Attending Physician at Dana-Farber and Instructor at Harvard Medical School, he was a post-doctoral fellow at Dana-Farber and the Whitehead Institute Center for Genomic Research of MIT. In 2004, Dr. Febbo joined Duke University Medical Center’s Institute of Genome Sciences and Policy until his return to UCSF.


 Speaker Profile

Ph.D., VP, Commercial Markets, Tempus Inc.

Biography
Suzanne Belinson, PhD, MPH, is Vice President of Commercial Markets at Tempus Labs Inc. Tempus is a technology company building the world’s largest library of clinical and molecular data and an operating system to make that data accessible and useful, starting with cancer. Her role focuses on commercial growth for Tempus through the development and execution of partnerships with organizations aiming to improve healthcare value and outcomes by leveraging molecular and clinical data.


 Speaker Profile

Ph.D., M.P.H., VP Health Economics and Outcomes Research, OptumLabs at UnitedHealth Group

Biography
Stacey DaCosta Byfield currently leads the Genomics Health Economics and Outcomes Research (HEOR) Team focused on conducting observational research studies using administrative claims, EHR/medical record data and other data sources, including laboratory results data.  Stacey joined UnitedHealth Group (UHG) in 2009 in the OptumInsight Life Sciences HEOR group where she started as a Senior Researcher focusing on oncology studies.  She later served as VP, Research of the Life Sciences HEOR group before moving to OptumLabs were she led the Data Scientist team and most recently the Oncology Focus Area Research Team. Prior to joining UHG, she worked in the Department of Drug Use Policy and Pharmacoeconomics at the University of Texas M.D. Anderson Cancer Center as a Pharmacoeconomics Research Specialist. In this capacity, her main responsibilities included developing research designs to evaluate clinical, economic and humanistic outcomes of pharmaceutical products and services. She holds a PhD in Tumor Biology from Georgetown University and completed a basic science fellowship at the National Cancer Institute where her work focused on identifying targets of pharmaceutical intervention for metastatic breast cancer. Stacey also received her MPH with a concentration in clinical effectiveness from the Harvard T. H. Chan School of Public Health and has completed the Program in Cancer Outcomes Research Training (PCORT) Fellowship, a jointly sponsored program by the Massachusetts General Hospital and the Dana-Farber Harvard Cancer Center in Boston, Massachusetts.